Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors
21 mars 2024 07h00 HE
|
Cancer Focus Fund; Eisbach Bio GmbH
Cancer Focus Fund is investing $4.5M for clinical trial of Eisbach's novel approach using synthetic lethality to kill PARP inhibitor resistant tumors
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for sarcoma
20 juin 2023 07h00 HE
|
Replay Bio
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for sarcoma First-in-human Phase 1 study of NY-ESO-1...
MD Anderson and ARTIDIS Announce Strategic Alliance to Advance Nanomechanical Technology Platform for Optimizing Cancer Treatment
03 oct. 2022 09h05 HE
|
ARTIDIS AG
HOUSTON and BASEL, Switzerland, Oct. 03, 2022 (GLOBE NEWSWIRE) -- ARTIDIS AG, the developer of the first nanomechanical technology platform for tissue analytics, and The University of Texas MD...
Houston Dash join Dynamo, MD Anderson in Making Cancer History
19 févr. 2020 12h00 HE
|
Houston Dynamo
HOUSTON, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center today announced the Houston Dash will join the institution's efforts toward one goal: end cancer....
Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center
22 juil. 2019 08h00 HE
|
Adaptimmune Therapeutics plc
- Compelling responses previously reported with ADP-A2M4 in sarcoma - - Use of low-dose radiation intended to enhance antitumor activity - PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 22,...
Summit Medical Group to Implement Altura’s Novel HCP Studies™ Mobile Platform to Support Expanding Patient Access to Clinical Studies
13 juin 2018 08h05 HE
|
Altura
MISSION VIEJO, Calif. and BERKELEY HEIGHTS, N.J., June 13, 2018 (GLOBE NEWSWIRE) -- Altura, the pioneer in expanding participation in health-related studies by streamlining connections between...
ConverGene Announces Sponsored Research Agreement with MD Anderson
18 sept. 2017 07h00 HE
|
ConverGene LLC
CAMBRIDGE, Md., Sept. 18, 2017 (GLOBE NEWSWIRE) -- ConverGene is pleased to announce that it has entered into a collaboration with The University of Texas MD Anderson Cancer Center (“MD Anderson”)...